Patents by Inventor Tong Zhu

Tong Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230293536
    Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, and use of the conjugate.
    Type: Application
    Filed: May 26, 2023
    Publication date: September 21, 2023
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • Patent number: 11695693
    Abstract: A packet transmission method, device, and system for network technologies are disclosed. A first network device receives, by using a first VPLS instance a packet to be sent to a user-side device connected to the second network device. The first network device forwards, based on an association relationship between the first VPLS instance and the first VPWS instance, the packet to a second VPWS instance in the second network device by using the first VPWS instance. A VPLS instance is associated with a VPWS instance in the first network device. A packet that is received by using the VPLS instance and that is to be sent to a user-side device can be forwarded by using the associated VPWS instance, so that pressure to learn a MAC address for packet transmission is reduced, and forwarding performance of the system is ensured.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: July 4, 2023
    Assignee: HUAWEI TECHNOLOGIES CO., LTD.
    Inventors: Haibo Wang, Xun Hu, Rongrong Hua, Tong Zhu
  • Patent number: 11679162
    Abstract: Provided in the present invention is an anti-5T4 antibody-drug conjugate and the use thereof. In particular, provided in the present invention is an anti-5T4 antibody-drug conjugate. Also provided in the present invention are the pharmaceutical use of the anti-5T4 antibody-drug conjugate and the effect thereof in inhibiting or preventing tumors.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 20, 2023
    Assignee: HANGZHOU ADCORIS BIOPHARMA CO., LTD.
    Inventors: Zhenwei Miao, Tong Zhu, Alisher B. Khasanov, Sheldon Cao, Zhaohui Li, Min Wu
  • Publication number: 20230096410
    Abstract: The present disclosure provides an innate immunity cell such as a gamma delta T (gdT) cell, Natural Killer (NK) cell, or macrophage having 2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid (DUPA) chemically conjugated to the cell surface. The DUPA-conjugated cells provided herein demonstrate increased cytotoxicity toward cancer cells expressing PSMA. DUPA-conjugated cells can be primary cells or cells of a cell line. Also provided are methods of conjugating DUPA to the surface of NK cells, gamma delta T (gdT) cells, or macrophages and methods of treating cancer using DUPA-conjugated NK cells, gamma delta T (gdT) cells, or macrophages.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Reyna Lim, Daniel Lee, Matthew Buschman, Tong Zhu, Alisher B. Khasanov
  • Publication number: 20220209995
    Abstract: A packet transmission method, device, and system are disclosed, and pertain to the field of network technologies. The system includes a first network device in a VPLS network and a second network device in a VPWS network. The first network device determines, based on a destination address carried in a received first packet, a virtual port corresponding to the destination address in a VPLS instance of the first network device, and sends the first packet to a second VPWS instance in the second network device based on the virtual port, where the virtual port is used to indicate a first VPWS instance in the first network device, and the second VPWS instance and the first VPWS instance are VPWS instances used to bear a same service.
    Type: Application
    Filed: December 23, 2021
    Publication date: June 30, 2022
    Inventors: Haibo Wang, Xun Hu, Rongrong Hua, Tong Zhu
  • Publication number: 20220210049
    Abstract: A packet processing method and a network device are provided. The method is applied to a network system, and the network system includes a first network device and a plurality of network devices separately connected to the first network device. The method includes: The first network device groups the plurality of network devices into a plurality of groups based on a service, where each of the plurality of groups includes at least one network device. The first network device determines one or more groups in the plurality of groups, and forwards packets of the service to one or more of the plurality of network devices in the one or more groups. In present application, a mode for forwarding the packets of the service can be flexibly selected according to a service requirement, to better meet the service requirement.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 30, 2022
    Inventors: Haibo WANG, Yi ZENG, Rongrong HUA, Tong ZHU
  • Publication number: 20220210060
    Abstract: A packet transmission method, device, and system for network technologies are disclosed. A first network device receives, by using a first VPLS instance a packet to be sent to a user-side device connected to the second network device. The first network device forwards, based on an association relationship between the first VPLS instance and the first VPWS instance, the packet to a second VPWS instance in the second network device by using the first VPWS instance. A VPLS instance is associated with a VPWS instance in the first network device. A packet that is received by using the VPLS instance and that is to be sent to a user-side device can be forwarded by using the associated VPWS instance, so that pressure to learn a MAC address for packet transmission is reduced, and forwarding performance of the system is ensured.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 30, 2022
    Inventors: Haibo WANG, Xun Hu, Rongrong Hua, Tong Zhu
  • Publication number: 20220159369
    Abstract: An electronic device includes a main body, a display disposed on the main body, and a sound-making assembly. The sound-making assembly includes a speaker box and a driving diaphragm located in the speaker box, the speaker box is disposed inside the main body or is formed using the main body and the display, where the main body includes a speaker grille corresponding to the speaker box, the driving diaphragm is fastened inside the speaker box and divides the speaker box into two sub-chambers, the speaker grille is coupled to one of the two sub-chambers, the driving diaphragm vibrates after receiving an audio signal, the driving diaphragm drives, through vibration of the driving diaphragm, air in the two sub-chambers to vibrate to make a sound, and the sound is propagated through the speaker grille.
    Type: Application
    Filed: February 24, 2020
    Publication date: May 19, 2022
    Inventors: Jie Su, Tong Zhu, Ligang Yu, Chunjian Li
  • Publication number: 20220118105
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Application
    Filed: November 3, 2021
    Publication date: April 21, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Publication number: 20220010005
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: February 16, 2021
    Publication date: January 13, 2022
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20220008553
    Abstract: Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 13, 2022
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • Patent number: 11218493
    Abstract: This disclosure relates to identity verification. In one aspect, a method includes obtaining verification information during a user application session of a user with an application component subsequent to a verification triggering request to perform identity verification on the user. A determination is made whether the verification information satisfies a first identity verification-free condition. When the verification information satisfies the first identity verification-free condition, an identity verification-free operation that does not include identity verification of the user is performed. When the verification information fails to satisfy the first identity verification-free condition, an identity verification process is performed to verify an identity of the user.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: January 4, 2022
    Assignee: Advanced New Technologies Co., Ltd.
    Inventors: Jue Mei, Xin Chen, Tong Zhu, Yiteng Tian
  • Publication number: 20210395391
    Abstract: Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided. The methods comprises administering to a subject in need there of an initial dose of about 50 mg to 500 mg of an anti-TFPI antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tong Zhu, Steven Arkin, Matthew H. Cardinal, Chay Ngee Lim, Satyaprakash Nayak
  • Patent number: 11191845
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Patent number: 11165894
    Abstract: This application discloses a housing assembly, including a housing, a decorating part, and an adhesive assembly. The housing is provided with a through hole. The decorating part includes a substrate and a decorating ring protruding from the substrate. An air hole is disposed on the substrate. The air hole is located on an outer side of the decorating ring. The decorating ring is at least partially accommodated in the through hole. A gap is formed between an outer peripheral side surface of the decorating ring and a hole wall of the through hole. The adhesive assembly is attached between the substrate and the housing in a sealed manner. The adhesive assembly is disposed around the decorating ring and the air hole, and a channel is formed between the adhesive assembly and the outer peripheral side surface of the decorating ring.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 2, 2021
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Shizhe Li, Hanwen Lu, Xiaotao Dai, Youying Lan, Tong Zhu
  • Patent number: 11132435
    Abstract: A method includes: training a prediction model with sample data; obtaining user information of a user as an input feature to the prediction model; predicting, using the prediction model according to a set of determination conditions, whether the user has forgotten a payment password associated with a payment application; and in response to predicting that the user has forgotten the payment password and detecting the user logging in the payment application with a login password different from the payment password, displaying a user interface for directing the user to a payment password resetting interface for resetting the payment password.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: September 28, 2021
    Assignee: ADVANCED NEW TECHNOLOGIES CO., LTD.
    Inventors: Yipeng Yang, Kangbei Jiang, Ning Wang, Hua Zhao, Tong Zhu
  • Publication number: 20210260211
    Abstract: There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).
    Type: Application
    Filed: April 26, 2021
    Publication date: August 26, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Hong Zhang, Alisher B. Khasanov, Gang Chen
  • Publication number: 20210252006
    Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 19, 2021
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • Publication number: 20210234948
    Abstract: This application discloses a housing assembly, including a housing, a decorating part, and an adhesive assembly. The housing is provided with a through hole. The decorating part includes a substrate and a decorating ring protruding from the substrate. An air hole is disposed on the substrate. The air hole is located on an outer side of the decorating ring. The decorating ring is at least partially accommodated in the through hole. A gap is formed between an outer peripheral side surface of the decorating ring and a hole wall of the through hole. The adhesive assembly is attached between the substrate and the housing in a sealed manner. The adhesive assembly is disposed around the decorating ring and the air hole, and a channel is formed between the adhesive assembly and the outer peripheral side surface of the decorating ring.
    Type: Application
    Filed: May 11, 2018
    Publication date: July 29, 2021
    Inventors: Shizhe Li, Hanwen Lu, Xiaotao Dai, Youying Lan, Tong Zhu
  • Publication number: 20210187119
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski